Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Condition: Rhinitis
MeSH terms: Rhinitis; Rhinitis, Allergic
Intervention: SB-705498; FP; placebo
Intervention description: 12mg intranasal; 200ug intranasal; placebo intranasal
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 70.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms
      induced by an allergen chamber challenge.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for
             several months per year, for more than 1 year and are not attributed to allergy,
             infections or nasal abnormalities.

          2. TNSS score of >=4 following screening allergen challenge chamber.

          3. Positive skin prick test for seasonal pollen

          4. Positive RAST for seasonal pollen

          5. Healthy as determined by responsible physician with the exception of mild asthma and
             AR

          6. Male or female between 18 and 65 years of age inclusive.

          7. A female subject is eligible to participate if she is of:

               -  Non-childbearing potential defined as pre-menopausal females with a \documented
                  tubal ligation or hysterectomy; or postmenopausal defined as 12 months of
                  spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
                  follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147
                  pmol/L) is confirmatory].

               -  Child-bearing potential and agrees to use one of the contraception methods listed
                  as instructed. Female subjects must agree to use contraception until 84 days
                  post-last treatment administration.

          8. Male subjects with female partners of child-bearing potential must agree to use one
             contraception as instructed. This must be followed from the time of the first dose of
             study medication until 84 days post-last treatment administration.

          9. Body weight ≥ 50 kg (males) and ≥45kg (females) and BMI within the range 19 - 29.9
             kg/m2 (inclusive).

         10. Screening pre-challenge FEV1 greater than or equal to 80% and baselines FEV1/FVC
             greater than or equal to 70% of predicted value.

         11. Capable of giving written informed consent.

         12. Average QTcB, < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

         13. AST and ALT < 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN

        Exclusion Criteria:

          1. Nasal abnormalities likely to affect the outcome of the study,

          2. History of frequent nosebleeds.

          3. Respiratory disease other than mild asthma

          4. A positive pre-study Hepatitis B or Hepatitis C result within 3 months of screening

          5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities

          6. Positive pre-study drug/alcohol/smoking screen.

          7. A positive test for HIV antibody.

          8. History of regular alcohol consumption within 6 months of the study defined as:

             • An average weekly intake of >14 drinks for males or >7 drinks for females.

          9. The subject has participated in a clinical trial and has received an investigational
             product within 30 days, 5 half-lives or twice the duration of the biological effect of
             the investigational product prior to D1.

         10. Exposure to more than four new chemical entities within 12 months prior to D1.

         11. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 7 days prior to the first dose of study medication.

         12. History of sensitivity to any of the study medications, or components

         13. Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

         14. Pregnant females as determined by positive serum or urine hCG test at screening or
             prior to dosing.

         15. Lactating females.

         16. Subject is mentally or legally incapacitated.

         17. Urine cotinine levels indicative of smoking